Characterization of the self-association of human interferon-α2b, albinterferon-α2b, and pegasys.

The self-association of human interferon-α2b (hIFN-α2b), albinterferon-α2b (a recombinant protein with human serum albumin and hIFN-α2b peptides fused together in a single polypeptide chain), and Pegasys (PEGylated hIFN-α2a) was characterized by analytical ultracentrifugation analyses. By examining the apparent sedimentation coefficient distribution profiles of each protein at different concentrations, it was concluded that the above three proteins are self-associating in albinterferon-α2b formulation buffer. By model fitting of sedimentation data using SEDANAL software, the stoichiometry and equilibrium constants of the self-association of these proteins were characterized. The self-association of hIFN-α2b results in the formation of stable dimers, fast-reversible tetramers, octamers, and hexadecamers. In contrast, although both albinterferon-α2b and Pegasys are self-associated, their self-association stoichiometries are significantly different from that of hIFN-α2b. The self-association of albinterferon-α2b results in the formation of reversible dimers and trimers, whereas the self-association of Pegasys gives only reversible dimers. The self-association behaviors of hIFN-α2b and albinterferon-α2b involves attractive electrostatic forces, which can be suppressed to a negligible level in low pH (pH 4.0-4.5) and high salt concentration (400 mM NaCl) buffer, allowing quantification of their size variant contents by sedimentation velocity analysis.

[1]  M. Brader,et al.  Effects of Non-Covalent Self-Association on the Subcutaneous Absorption of a Therapeutic Peptide , 1998, Pharmaceutical Research.

[2]  B. Kuhlman,et al.  An exceptionally stable helix from the ribosomal protein L9: implications for protein folding and stability. , 1997, Journal of molecular biology.

[3]  H. K. Schachman Ultracentrifugation in biochemistry , 1959 .

[4]  P. Schuck On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. , 2003, Analytical biochemistry.

[5]  A. Schacher,et al.  Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). , 2003, Protein expression and purification.

[6]  B. Nardelli,et al.  Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. Matthews,et al.  The power of two: protein dimerization in biology. , 2004, Trends in biochemical sciences.

[8]  M. Fiscella,et al.  Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C , 2007, Nature Biotechnology.

[9]  Kathryn C. Zoon,et al.  Mini ReviewHuman Interferons Alpha, Beta and Omega , 2004 .

[10]  P. Schuck,et al.  Determination of the sedimentation coefficient distribution by least-squares boundary modeling. , 2000, Biopolymers.

[11]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.

[12]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[13]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[14]  Theodore W Randolph,et al.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.

[15]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[16]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[17]  R. Redfield,et al.  A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon-α Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-α-Based Therapy , 2006, Antiviral Therapy.

[18]  S. Maher,et al.  Interferon: cellular executioner or white knight? , 2007, Current medicinal chemistry.

[19]  W. Stafford,et al.  Analysis of heterologous interacting systems by sedimentation velocity: curve fitting algorithms for estimation of sedimentation coefficients, equilibrium and kinetic constants. , 2004, Biophysical chemistry.

[20]  Yatin R. Gokarn,et al.  Hydrodynamic behavior and thermal stability of a PEGylated protein: Studies with hen egg lysozyme , 2003 .

[21]  J. Kelly,et al.  Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. , 2005, Biochemistry.

[22]  H. Senn,et al.  Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.

[23]  G. Panayotou,et al.  Intermolecular Interactions of the p85α Regulatory Subunit of Phosphatidylinositol 3-Kinase* , 1999, The Journal of Biological Chemistry.

[24]  R. Chance,et al.  Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. , 2001, Critical reviews in therapeutic drug carrier systems.

[25]  M. Fiscella,et al.  A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. , 2006, Journal of hepatology.

[26]  J. Philo Is any measurement method optimal for all aggregate sizes and types? , 2006, The AAPS Journal.

[27]  John P. Gabrielson,et al.  Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. , 2007, Journal of pharmaceutical sciences.